Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2015 (2015), Article ID 216375, 13 pages
http://dx.doi.org/10.1155/2015/216375
Review Article

Nanosuspension Technologies for Delivery of Poorly Soluble Drugs

1Mawson Institute, University of South Australia, Mawson Lakes, Adelaide, SA 5095, Australia
2School of Engineering, University of South Australia, Mawson Lakes, Adelaide, SA 5095, Australia
3Ian Wark Research Institute, University of South Australia, Mawson Lakes, Adelaide, SA 5095, Adelaide, Australia

Received 15 August 2014; Accepted 15 October 2014

Academic Editor: Haifeng Chen

Copyright © 2015 Roya Yadollahi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao, “Nanonization strategies for poorly water-soluble drugs,” Drug Discovery Today, vol. 16, no. 7-8, pp. 354–360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Xiaohui, S. Jin, L. Mo, and H. Zhonggui, “Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs,” Current Nanoscience, vol. 5, no. 4, pp. 417–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Mercadante and V. Vitrano, “Pain in patients with lung cancer: pathophysiology and treatment,” Lung Cancer, vol. 68, no. 1, pp. 10–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. S. Bergström, C. M. Wassvik, K. Johansson, and I. Hubatsch, “Poorly soluble marketed drugs display solvation limited solubility,” Journal of Medicinal Chemistry, vol. 50, no. 23, pp. 5858–5862, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. K. Bhal, K. Kassam, I. G. Peirson, and G. M. Pearl, “The rule of five revisited: applying log D in place of log P in drug-likeness filters,” Molecular Pharmaceutics, vol. 4, no. 4, pp. 556–560, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Wassvik, A. G. Holmén, R. Draheim, P. Artursson, and C. A. S. Bergström, “Molecular characteristics for solid-state limited solubility,” Journal of Medicinal Chemistry, vol. 51, no. 10, pp. 3035–3039, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Pifferi and P. Restani, “The safety of pharmaceutical excipients,” Il Farmaco, vol. 58, no. 8, pp. 541–550, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. A. K. Nayak and P. P. Panigrahi, “Solubility enhancement of etoricoxib by cosolvency approach,” ISRN Physical Chemistry, vol. 2012, Article ID 820653, 5 pages, 2012. View at Publisher · View at Google Scholar
  9. S. Nippe and S. General, “Parenteral oil-based drospirenone microcrystal suspensions—evaluation of physicochemical stability and influence of stabilising agents,” International Journal of Pharmaceutics, vol. 416, no. 1, pp. 181–188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. P. Lakshmi, M. A. Kumar, M. V. Krishna, K. A. Vijetha, and G. Ashwini, “Formulation development of irbesartan (poorly water-soluble drug) immediate release tablets,” International Research Journal of Pharmacy, vol. 3, pp. 117–120, 2012. View at Google Scholar
  11. M. J. Arias, J. R. Moyano, and J. M. Ginés, “Investigation of the triamterene-β-cyclodextrin system prepared by co-grinding,” International Journal of Pharmaceutics, vol. 153, no. 2, pp. 181–189, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. S. I. Farag Badawy, M. M. Ghorab, and C. M. Adeyeye, “Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates,” International Journal of Pharmaceutics, vol. 128, no. 1-2, pp. 45–54, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. M. T. Esclusa-Díaz, M. Guimaraens-Méndez, M. B. Pérez-Marcos, J. L. Vila-Jato, and J. J. Torres-Labandeira, “Characterization and in vitro dissolution behaviour of ketoconazole/β- and 2-hydroxypropyl-β-cyclodextrin inclusion compounds,” International Journal of Pharmaceutics, vol. 143, no. 2, pp. 203–210, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Jarvinen, K. Jarvinen, N. Schwarting, and V. J. Stella, “β-Cyclodextrin derivatives, SBE4-β-CD and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs,” Journal of Pharmaceutical Sciences, vol. 84, no. 3, pp. 295–299, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. T. L. Rogers, A. C. Nelsen, J. Hu et al., “A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: Spray-freezing into liquid,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 54, no. 3, pp. 271–280, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. C. A. Ventura, S. Tirendi, G. Puglisi, E. Bousquet, and L. Panza, “Improvement of water solubility and dissolution rate of ursodeoxycholic acid and chenodeoxycholic acid by complexation with natural and modified β-cyclodextrins,” International Journal of Pharmaceutics, vol. 149, no. 1, pp. 1–13, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. A. G. Floyd, “Top ten considerations in the development of parenteral emulsions,” Pharmaceutical Science and Technology Today, vol. 2, no. 4, pp. 134–143, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Nakano, “Places of emulsions in drug delivery,” Advanced Drug Delivery Reviews, vol. 45, no. 1, pp. 1–4, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Lawrence and G. D. Rees, “Microemulsion-based media as novel drug delivery systems,” Advanced Drug Delivery Reviews, vol. 45, no. 1, pp. 89–121, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. M. P. de Oliveira, E. Garcion, N. Venisse, J.-P. Benoît, W. Couet, and J.-C. Olivier, “Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 mice,” Pharmaceutical Research, vol. 22, no. 11, pp. 1898–1905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Moneghini, I. Kikic, D. Voinovich, B. Perissutti, and J. Filipović-Grčić, “Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution,” International Journal of Pharmaceutics, vol. 222, no. 1, pp. 129–138, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Serajuddln, “Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs,” Journal of Pharmaceutical Sciences, vol. 88, no. 10, pp. 1058–1066, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Zerrouk, C. Chemtob, P. Arnaud, S. Toscani, and J. Dugue, “In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions,” International Journal of Pharmaceutics, vol. 225, no. 1-2, pp. 49–62, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. G. C. S. Rao, M. S. Kumar, N. Mathivanan, and M. E. B. Rao, “Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems,” Pharmazie, vol. 59, no. 1, pp. 5–9, 2004. View at Google Scholar · View at Scopus
  25. R. H. Müller, “Nanosuspension for the i.v. administration of poorly soluble drugs—stability during sterilization and long-term storage,” in Proceedings of the 22nd International Symposium on Controlled Release of Bioactive Materials, pp. 574–575, 1995.
  26. R. Becker, R. H. Muller, B. Kruss, and K. Peters, “Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution,” US Patent, No. 5858410, 1999.
  27. G. G. Liversidge, K. C. Cundy, J. F. Bishop, and D. A. Czekai, “Surface modified drug nanoparticles,” US Patent no. 5145684, 1992.
  28. P. Gassmann, M. List, A. Schweitzer, and H. Sucker, “Hydrosols—alternatives for the parenteral application of poorly water soluble drugs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 40, no. 2, pp. 64–72, 1994. View at Google Scholar · View at Scopus
  29. R. H. Müller, C. Jacobs, and O. Kayser, “Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future,” Advanced Drug Delivery Reviews, vol. 47, no. 1, pp. 3–19, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. R. H. Müller, K. Peters, R. Becker et al., “Nanosuspensions—a novel formulation for the IV administration of poorly soluble drugs,” in Proceedings of the 1st World Meeting of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, APGI, Budapest, Hungary, 1995.
  31. R. H. Muller, K. Peters, R. Becker, and B. Kruss, “Nanosuspensions for the i.v. administration of poorly soluble drugs: stability during sterilization and long-term storage,” Proceedings of the Controlled Release Society, no. 22, pp. 574–575, 1995. View at Google Scholar · View at Scopus
  32. R. H. Muller, R. Becker, B. Kruss, and K. Peters, “Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution,” US Patent 5,858,410, 1999.
  33. G. P. Sanganwar, S. Sathigari, R. J. Babu, and R. B. Gupta, “Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement,” European Journal of Pharmaceutical Sciences, vol. 39, no. 1–3, pp. 164–174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Zhang, T. Tan, L. Gao, W. Zhao, and P. Wang, “Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies,” Drug Development and Industrial Pharmacy, vol. 33, no. 5, pp. 569–575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Zhang, N. Kohler, and M. Zhang, “Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake,” Biomaterials, vol. 23, no. 7, pp. 1553–1561, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Blanco, C. W. Kessinger, B. D. Sumer, and J. Gao, “Multifunctional micellar nanomedicine for cancer therapy,” Experimental Biology and Medicine, vol. 234, no. 2, pp. 123–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Matsumura and K. Kataoka, “Preclinical and clinical studies of anticancer agent-incorporating polymer micelles,” Cancer Science, vol. 100, no. 4, pp. 572–579, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, “A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability,” Pharmaceutical Research, vol. 12, no. 3, pp. 413–420, 1995. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue, “Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications,” International Journal of Pharmaceutics, vol. 420, no. 1, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Martinez, L. Augsburger, T. Johnston, and W. W. Jones, “Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part I: biopharmaceutics and formulation considerations,” Advanced Drug Delivery Reviews, vol. 54, no. 6, pp. 805–824, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Kesisoglou, S. Panmai, and Y. Wu, “Nanosizing—oral formulation development and biopharmaceutical evaluation,” Advanced Drug Delivery Reviews, vol. 59, no. 7, pp. 631–644, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. G. J. Vergote, C. Vervaet, I. van Driessche et al., “An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen,” International Journal of Pharmaceutics, vol. 219, no. 1-2, pp. 81–87, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. M. V. Chaubal, “Application of formulation technologies in lead candidate selection and optimization,” Drug Discovery Today, vol. 9, no. 14, pp. 603–609, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, “Nanosizing: a formulation approach for poorly-water-soluble compounds,” European Journal of Pharmaceutical Sciences, vol. 18, no. 2, pp. 113–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Hu, K. P. Johnston, and R. O. Williams III, “Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs,” Drug Development and Industrial Pharmacy, vol. 30, no. 3, pp. 233–245, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. G. G. Liversidge, K. C. Cundy, J. F. Bishop, and D. A. Czekai, “Surface modified drug nanoparticles,” US Patents 5,145,689, 1992.
  47. J. Chingunpituk, “Nanosuspension technology for drug delivery,” Walailak Journal of Science and Technology, vol. 4, no. 2, pp. 139–153, 2007. View at Google Scholar
  48. S. Bansal, M. Bansal, and R. Kumria, “Nanocrystals: current strategies and trends,” International Journal of Research in Pharmaceutical and Biomedical Sciences, vol. 3, no. 1, pp. 406–419, 2012. View at Google Scholar
  49. J.-U. A. H. Junghanns and R. H. Müller, “Nanocrystal technology, drug delivery and clinical applications,” International Journal of Nanomedicine, vol. 3, no. 3, pp. 295–309, 2008. View at Google Scholar · View at Scopus
  50. J. Moschwitzer, G. Achleitner, H. Pomper, and R. H. Müller, “Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 58, no. 3, pp. 615–619, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. Y.-J. Chen, X.-L. Yang, X.-L. Zhao, and H.-B. Xu, “Preparation of oleanolic acid nanosuspension,” Zhongguo Yaoxue Zazhi, vol. 41, no. 12, pp. 924–927, 2006. View at Google Scholar · View at Scopus
  52. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, and K. Amighi, “Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine,” International Journal of Pharmaceutics, vol. 299, no. 1-2, pp. 167–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. M. P. Kumar, Y. M. Rao, and S. Apte, “Improved bioavailability of albendazole following oral administration of nanosuspension in rats,” Current Nanoscience, vol. 3, no. 2, pp. 191–194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Langguth, A. Hanafy, D. Frenzel et al., “Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound,” Drug Development and Industrial Pharmacy, vol. 31, no. 3, pp. 319–329, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. R. H. Müller and C. Jacobs, “Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability,” International Journal of Pharmaceutics, vol. 237, no. 1-2, pp. 151–161, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Gao, D. Zhang, and M. Chen, “Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system,” Journal of Nanoparticle Research, vol. 10, no. 5, pp. 845–862, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. R. H. Muller, C. Jacobs, and O. Kayser, “Nanosuspensions for the formulation of poorly soluble drugs,” in Pharmaceutical Emulsions and Suspensions, vol. 105, pp. 383–407, 2000. View at Google Scholar
  58. K. P. Krause, O. Kayser, K. Mäder, R. Gust, and R. H. Müller, “Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation,” International Journal of Pharmaceutics, vol. 196, no. 2, pp. 169–172, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Kumar, S. K. Sahoo, P. Globale et al., “Review on solubility enhancement techniques for hydrophobic drugs,” Pharmacie Globale, vol. 3, no. 3, pp. 001–007, 2011. View at Google Scholar
  60. G. A. Reddy, “Nanosuspension technology—a review,” IJPI's Journal of Pharmaceutics and Cosmetology, vol. 2, no. 8, pp. 47–52, 2012. View at Google Scholar
  61. C. M. Keck and R. H. Müller, “Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 62, no. 1, pp. 3–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Lemke, A. F. Kiderlen, B. Petri, and O. Kayser, “Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 4, pp. 597–603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Hanafy, H. Spahn-Langguth, G. Vergnault et al., “Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug,” Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 419–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Jacobs and R. H. Müller, “Production and characterization of a budesonide nanosuspension for pulmonary administration,” Pharmaceutical Research, vol. 19, no. 2, pp. 189–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Hernández-Trejo, O. Kayser, H. Steckel, and R. H. Müller, “Characterization of nebulized buparvaquone nanosuspensions—effect of nebulization technology,” Journal of Drug Targeting, vol. 13, no. 8-9, pp. 499–507, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Jacobs, O. Kayser, and R. H. Müller, “Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone,” International Journal of Pharmaceutics, vol. 214, no. 1-2, pp. 3–7, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Peters, S. Leitzke, J. E. Diederichs et al., “Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 1, pp. 77–83, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. M. A. Kassem, A. A. Abdel Rahman, M. M. Ghorab, M. B. Ahmed, and R. M. Khalil, “Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs,” International Journal of Pharmaceutics, vol. 340, no. 1-2, pp. 126–133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Gao, D. Zhang, M. Chen et al., “Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions,” International Journal of Pharmaceutics, vol. 355, no. 1-2, pp. 321–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Ben Zirar, A. Astier, M. Muchow, and S. Gibaud, “Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 2, pp. 649–656, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Jacobs, O. Kayser, and R. H. Müller, “Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide,” International Journal of Pharmaceutics, vol. 196, no. 2, pp. 161–164, 2000. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Xiong, W. Lu, J. Li, P. Wang, R. Xu, and T. Chen, “Preparation and characterization of intravenously injectable nimodipine nanosuspension,” International Journal of Pharmaceutics, vol. 350, no. 1-2, pp. 338–343, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. O. Kayser, C. Olbrich, V. Yardley, A. F. Kiderlen, and S. L. Croft, “Formulation of amphotericin B as nanosuspension for oral administration,” International Journal of Pharmaceutics, vol. 254, no. 1, pp. 73–75, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Sun, S. Mao, Y. Shi, L. C. Li, and L. Fang, “Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption,” Journal of Pharmaceutical Sciences, vol. 100, no. 8, pp. 3365–3373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. R. H. Müller, S. Gohla, and C. M. Keck, “State of the art of nanocrystals—special features, production, nanotoxicology aspects and intracellular delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 78, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. B. K. Nanjwadea, G. K. Derkar, H. Bechra, and F. V. Manvi, “Nanosized technological approaches for the delivery of poorly water soluble drugs,” Iranian Journal of Pharmaceutical Sciences, vol. 6, no. 3, pp. 149–162, 2010. View at Google Scholar
  77. A. Akkar and R. H. Müller, “Intravenous itraconazole emulsions produced by SolEmuls technology,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 56, no. 1, pp. 29–36, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Kocbek, S. Baumgartner, and J. Kristl, “Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs,” International Journal of Pharmaceutics, vol. 312, no. 1-2, pp. 179–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Trotta, M. Gallarate, F. Pattarino, and S. Morel, “Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions,” Journal of Controlled Release, vol. 76, no. 1-2, pp. 119–128, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Dandagi, S. Kerur, V. Mastiholimath, A. Gadad, and A. Kulkarni, “Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution,” Iranian Journal of Pharmaceutical Research, vol. 8, no. 2, pp. 79–86, 2009. View at Google Scholar · View at Scopus
  81. W. Mehnert and K. Mäder, “Solid lipid nanoparticles: production, characterization and applications,” Advanced Drug Delivery Reviews, vol. 47, no. 2-3, pp. 165–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Ahlin, J. Kristl, and J. Šmid-Korbar, “Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions,” Acta Pharmaceutica, vol. 48, no. 4, pp. 259–267, 1998. View at Google Scholar · View at Scopus
  83. S. Bosselmann and R. O. Williams III, “Route-specific challenges in the delivery of poorly water-soluble drugs,” in Formulating Poorly Water Soluble Drugs, R. O. Williams III, A. B. Watts, and D. A. Miller, Eds., pp. 1–2, Springer, New York, NY, USA, 2012. View at Google Scholar
  84. V. B. Patravale, A. A. Date, and R. M. Kulkarni, “Nanosuspensions: a promising drug delivery strategy,” Journal of Pharmacy and Pharmacology, vol. 56, no. 7, pp. 827–840, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Verma and D. Burgess, “Solid nanosuspensions: the emerging technology and pharmaceutical applications as nanomedicine,” in Pharmaceutical Suspensions, A. K. Kulshreshtha, O. N. Singh, and G. M. Wall, Eds., pp. 285–318, Springer, New York, NY, USA, 2010. View at Google Scholar
  86. E. M. Merisko-Liversidge and G. G. Liversidge, “Drug nanoparticles: formulating poorly water-soluble compounds,” Toxicologic Pathology, vol. 36, no. 1, pp. 43–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Wang, D. Zhang, Z. Liu et al., “In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery,” Nanotechnology, vol. 21, no. 15, Article ID 155104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Mhatre, R. Chinchole, U. Desai, and R. Chavan, “Review: nanosuspensions,” International Journal of Pharmaceutical Sciences Review and Research, vol. 13, no. 1, pp. 118–124, 2012. View at Google Scholar
  89. H. G. Merkus, “Dynamic light scattering,” in Particle Size Measurements, pp. 299–317, Springer, 2008. View at Publisher · View at Google Scholar
  90. V. Teeranachaideekul, V. B. Junyaprasert, E. B. Souto, and R. H. Müller, “Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology,” International Journal of Pharmaceutics, vol. 354, no. 1-2, pp. 227–234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Gaumet, A. Vargas, R. Gurny, and F. Delie, “Nanoparticles for drug delivery: the need for precision in reporting particle size parameters,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 69, no. 1, pp. 1–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Chingunpitak, S. Puttipipatkhachorn, P. Chavalitshewinkoon-Petmitr, Y. Tozuka, K. Moribe, and K. Yamamoto, “Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method,” Drug Development and Industrial Pharmacy, vol. 34, no. 3, pp. 314–322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. L. Lindfors, P. Skantze, U. Skantze, J. Westergren, and U. Olsson, “Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth,” Langmuir, vol. 23, no. 19, pp. 9866–9874, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. R. F. Domingos, M. A. Baalousha, Y. Ju-Nam et al., “Characterizing manufactured nanoparticles in the environment: multimethod determination of particle sizes,” Environmental Science and Technology, vol. 43, no. 19, pp. 7277–7284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. E. Haustein and P. Schwille, “Fluorescence correlation spectroscopy: novel variations of an established technique,” Annual Review of Biophysics and Biomolecular Structure, vol. 36, pp. 151–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. V. Filipe, A. Hawe, and W. Jiskoot, “Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates,” Pharmaceutical Research, vol. 27, no. 5, pp. 796–810, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. N. Manh Thang, H. Geckeis, J. I. Kim, and H. P. Beck, “Application of the flow field flow fractionation (FFFF) to the characterization of aquatic humic colloids: evaluation and optimization of the method,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 181, no. 1, pp. 289–301, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Lapresta-Fernández, A. Salinas-Castilloa, S. Anderson de la Llana et al., “A general perspective of the characterization and quantification of nanoparticles: imaging, spectroscopic, and separation techniques,” Critical Reviews in Solid State and Materials Sciences, vol. 39, no. 6, pp. 423–458, 2014. View at Publisher · View at Google Scholar
  99. M. G. Fakes, B. J. Vakkalagadda, F. Qian et al., “Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches,” International Journal of Pharmaceutics, vol. 370, no. 1-2, pp. 167–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Kawakami, “Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs,” Advanced Drug Delivery Reviews, vol. 64, no. 6, pp. 480–495, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Tian, J. A. Zeitler, C. J. Strachan, D. J. Saville, K. C. Gordon, and T. Rades, “Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy,” Journal of Pharmaceutical and Biomedical Analysis, vol. 40, no. 2, pp. 271–280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. J. M. Chalmers and G. Dent, Vibrational Spectroscopic Methods in Pharmaceutical Solid-State Characterization, Wiley-VCH, Weinheim, Germany, 2006.
  103. Y. Ikeda, Y. Ishihara, T. Moriwaki, E. Kato, and K. Terada, “A novel analytical method for pharmaceutical polymorphs by terahertz spectroscopy and the optimization of crystal form at the discovery stage,” Chemical & Pharmaceutical Bulletin, vol. 58, no. 1, pp. 76–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Otsuka, J.-I. Nishizawa, J. Shibata, and M. Ito, “Quantitative evaluation of mefenamic acid polymorphs by terahertz-chemometrics,” Journal of Pharmaceutical Sciences, vol. 99, no. 9, pp. 4048–4053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Bond, S. Allen, M. C. Davies et al., “Differential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials,” International Journal of Pharmaceutics, vol. 243, no. 1-2, pp. 71–82, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. B. van Eerdenbrugh, L. Froyen, J. A. Martens et al., “Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling,” International Journal of Pharmaceutics, vol. 338, no. 1-2, pp. 198–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Gao, Z. Li, M. Sun et al., “Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer,” Drug Development and Industrial Pharmacy, vol. 36, no. 10, pp. 1225–1234, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Shi, Literature Review of Steric Stabilization, Center for Industrial Sensors and Measurements, Ohio State University, 2002.
  109. S. R. Deshiikan and K. D. Papadopoulos, “Modified Booth equation for the calculation of zeta potential,” Colloid and Polymer Science, vol. 276, no. 2, pp. 117–124, 1998. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. Liang and J. Binner, “Effect of triblock copolymer non-ionic surfactants on the rheology of 3 mol% yttria stabilised zirconia nanosuspensions,” Ceramics International, vol. 34, no. 2, pp. 293–297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Chaurasia, D. Singh, and D. S. Nimisha, “A review on nanosuspensions promising drug delivery strategy,” Current Pharma Research, vol. 3, no. 1, pp. 764–776, 2012. View at Google Scholar
  112. D. Quintanar-Guerrero, A. Ganem-Quintanar, E. Allémann, H. Fessi, and E. Doelker, “Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D,L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique,” Journal of Microencapsulation, vol. 15, no. 1, pp. 107–119, 1998. View at Publisher · View at Google Scholar · View at Scopus
  113. R. H. Muller and C. M. Keck, “Challenges and solutions for the delivery of biotech drugs—a review of drug nanocrystal technology and lipid nanoparticles,” Journal of Biotechnology, vol. 113, no. 1–3, pp. 151–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. B. E. Rabinow, “Nanosuspensions in drug delivery,” Nature Reviews Drug Discovery, vol. 3, no. 9, pp. 785–796, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. Y.-X. Zhao, H.-Y. Hua, M. Chang, W.-J. Liu, Y. Zhao, and H.-M. Liu, “Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions,” International Journal of Pharmaceutics, vol. 392, no. 1-2, pp. 64–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. H. Lamb, Hydrodynamics, Cambridge University Press, Cambridge, UK, 6th edition, 1993.
  117. Y. Liu, P. Xie, D. Zhang, and Q. Zhang, “A mini review of nanosuspensions development,” Journal of Drug Targeting, vol. 20, no. 3, pp. 209–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. R. H. Muller, J. Moschwitzer, and F. N. Bushrab, “Manufacturing of nanoparticles by milling and homogenization techniques,” in Nanoparticle Technology for Drug Delivery (Drugs and the Pharmaceutical Sciences), vol. 159, pp. 21–51, CRC Press, New York, NY, USA, 2006. View at Google Scholar
  119. B. van Eerdenbrugh, G. van den Mooter, and P. Augustijns, “Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products,” International Journal of Pharmaceutics, vol. 364, no. 1, pp. 64–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. V. E. Bernard, V. Sofie, M. Johan A et al., “Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions—a case study with itraconazole,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 2, pp. 590–596, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. W. C. N. Charman and V. J. Stella, Lymphatic Transport of Drugs, CRC Press, Boca Raton, Fla, USA, 1992.
  122. J. P. K. Tan, Q. Wang, and K. C. Tam, “Control of burst release from nanogels via layer by layer assembly,” Journal of Controlled Release, vol. 128, no. 3, pp. 248–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. O. Kayser, “A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications,” International Journal of Pharmaceutics, vol. 214, no. 1-2, pp. 83–85, 2001. View at Publisher · View at Google Scholar · View at Scopus
  124. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, “Factors affecting the clearance and biodistribution of polymeric nanoparticles,” Molecular Pharmaceutics, vol. 5, no. 4, pp. 505–515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Lode, I. Fichtner, J. Kreuter, A. Berndt, J. E. Diederichs, and R. Reszka, “Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models,” Pharmaceutical Research, vol. 18, no. 11, pp. 1613–1619, 2001. View at Publisher · View at Google Scholar · View at Scopus
  126. N. Z. Wu, D. Da, T. L. Rudoll, D. Needham, A. R. Whorton, and M. W. Dewhirst, “Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue,” Cancer Research, vol. 53, no. 16, pp. 3765–3770, 1993. View at Google Scholar · View at Scopus
  127. J. Kreuter, V. E. Petrov, D. A. Kharkevich, and R. N. Alyautdin, “Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles,” Journal of Controlled Release, vol. 49, no. 1, pp. 81–87, 1997. View at Publisher · View at Google Scholar · View at Scopus
  128. F. Gabor, C. Fillafer, L. Neutsch, G. Ratzinger, and M. Wirth, “Improving oral delivery,” in Handbook of Experimental Pharmacology, vol. 197 of Drug Delivery, pp. 345–398, 2010. View at Google Scholar
  129. S. V. Sastry, J. R. Nyshadham, and J. A. Fix, “Recent technological advances in oral drug delivery. A review,” Pharmaceutical Science and Technology Today, vol. 3, no. 4, pp. 138–145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  130. Y. Chen, J. Liu, X. Yang, X. Zhao, and H. Xu, “Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect,” Journal of Pharmacy and Pharmacology, vol. 57, no. 2, pp. 259–264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. T. Venkatesh, A. K. Reddy, J. Uma Maheswari, M. Deena Dalith, and C. K. Ashok Kumar, “Nanosuspensions: ideal approach for the drug delivery of poorly water soluble drugs,” Der Pharmacia Lettre, vol. 3, no. 2, pp. 203–213, 2011. View at Google Scholar · View at Scopus
  132. N. Arunkumar, M. Deecaraman, and C. Rani, “Nanosuspension technology and its applications in drug delivery,” Asian Journal of Pharmaceutics, vol. 3, no. 3, pp. 168–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. Y. Shi, W. Porter, T. Merdan, and L. C. Li, “Recent advances in intravenous delivery of poorly water-soluble compounds,” Expert Opinion on Drug Delivery, vol. 6, no. 12, pp. 1261–1282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. K. K. Jain, “Drug delivery systems—an overview,” Methods in Molecular Biology, vol. 437, pp. 1–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. S. Bhalla, “Parenteral drug delivery,” in Gibaldi's Drug Delivery Systems in Pharmaceutical Care, M. Lee and A. Desai, Eds., p. 107, ASHP, Bethesda, Md, USA, 2007. View at Google Scholar
  136. H. Lou, X. Zhang, L. Gao et al., “In vitro and in vivo antitumor activity of oridonin nanosuspension,” International Journal of Pharmaceutics, vol. 379, no. 1-2, pp. 181–186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  137. L. Borgström, “The importance of the device in asthma therapy,” Respiratory Medicine, vol. 95, supplement B, pp. S26–S29, 2001. View at Google Scholar · View at Scopus
  138. H. M. Courrier, N. Butz, and T. F. Vandamme, “Pulmonary drug delivery systems: recent developments and prospects,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 19, no. 4-5, pp. 425–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  139. X. Liao and T. S. Wiedmann, “Solubilization of cationic drugs in lung surfactant,” Pharmaceutical Research, vol. 20, no. 11, pp. 1858–1863, 2003. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Beck-Broichsitter, “Pulmonary drug delivery with nanoparticles,” in Nanomedicine in Health and Disease, R. J. Hunter and V. R. Preedy, Eds., pp. 229–248, CRC Press, New York, NY, USA, 2011. View at Google Scholar
  141. S. Dhiman, T. G. Singh, and Dharmila, “Nanosuspension: a recent approach for nano drug delivery system,” International Journal of Current Pharmaceutical Research, vol. 3, no. 4, pp. 96–101, 2011. View at Google Scholar
  142. M. M. Bailey and C. J. Berkland, “Nanoparticle formulations in pulmonary drug delivery,” Medicinal Research Reviews, vol. 29, no. 1, pp. 196–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. K. A. Foster, M. Yazdanian, and K. L. Audus, “Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium,” Journal of Pharmacy and Pharmacology, vol. 53, no. 1, pp. 57–66, 2001. View at Publisher · View at Google Scholar · View at Scopus
  144. R. Gaudana, J. Jwala, S. H. S. Boddu, and A. K. Mitra, “Recent perspectives in ocular drug delivery,” Pharmaceutical Research, vol. 26, no. 5, pp. 1197–1216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. H. Gupta, M. Aqil, R. K. Khar, A. Ali, A. Bhatnagar, and G. Mittal, “Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 2, pp. 324–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. R. C. Nagarwal, S. Kant, P. N. Singh, P. Maiti, and J. K. Pandit, “Polymeric nanoparticulate system: a potential approach for ocular drug delivery,” Journal of Controlled Release, vol. 136, no. 1, pp. 2–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. R. Pignatello, C. Bucolo, G. Spedalieri, A. Maltese, and G. Puglisi, “Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application,” Biomaterials, vol. 23, no. 15, pp. 3247–3255, 2002. View at Publisher · View at Google Scholar · View at Scopus
  148. S. Das and P. K. Suresh, “Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 7, no. 2, pp. 242–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. S. Gupta, M. K. Samanta, and A. M. Raichur, “Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy,” AAPS PharmSciTech, vol. 11, no. 1, pp. 322–335, 2010. View at Publisher · View at Google Scholar · View at Scopus